癌チューブリン阻害剤の世界市場（～2026年）

• 英文タイトル：Global Cancer Tubulin Inhibitors Market Insights and Forecast to 2026

• レポートコード：MRC2-11QY03653 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、116ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は癌チューブリン阻害剤のグローバル市場について調査・分析したレポートです。種類別（ドセタキセル、トラスツズマブエムタンシン、アブラキサン、ブレンツキシマブベドチン、カバジタキセル）市場規模、用途別（非小細胞肺癌、前立腺癌、乳癌、結腸直腸癌、卵巣癌）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別癌チューブリン阻害剤の競争状況、市場シェア ・世界の癌チューブリン阻害剤市場：種類別市場規模 2015年-2020年（ドセタキセル、トラスツズマブエムタンシン、アブラキサン、ブレンツキシマブベドチン、カバジタキセル） ・世界の癌チューブリン阻害剤市場：種類別市場規模予測 2021年-2026年（ドセタキセル、トラスツズマブエムタンシン、アブラキサン、ブレンツキシマブベドチン、カバジタキセル） ・世界の癌チューブリン阻害剤市場：用途別市場規模 2015年-2020年（非小細胞肺癌、前立腺癌、乳癌、結腸直腸癌、卵巣癌） ・世界の癌チューブリン阻害剤市場：用途別市場規模予測 2021年-2026年（非小細胞肺癌、前立腺癌、乳癌、結腸直腸癌、卵巣癌） ・北米の癌チューブリン阻害剤市場分析：米国、カナダ ・ヨーロッパの癌チューブリン阻害剤市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの癌チューブリン阻害剤市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の癌チューブリン阻害剤市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの癌チューブリン阻害剤市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Abraxis Biosciences、Agensys、Amgen、Celgene、Eagle Pharmaceuticals、Endocyte、Genentech、Immunogen、Modra Pharmaceuticals、Pierre Fabre、Roche、Sanofi-Aventis、Seattle Genetics、Tocris Bioscience ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Market Analysis and Insights: Global Cancer Tubulin Inhibitors Market
The global Cancer Tubulin Inhibitors market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Cancer Tubulin Inhibitors Scope and Market Size
Cancer Tubulin Inhibitors market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Cancer Tubulin Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Cancer Tubulin Inhibitors market is segmented into
Docetaxel
Trastuzumab Emtansine
Abraxane
Brentuximab Vedotin
Cabazitaxel

Segment by Application, the Cancer Tubulin Inhibitors market is segmented into
Non Small Cell Lung Cancer
Prostate Cancer
Breast Cancer
Colorectal Cancer
Ovarian Cancer

Regional and Country-level Analysis
The Cancer Tubulin Inhibitors market is analysed and market size information is provided by regions (countries).
The key regions covered in the Cancer Tubulin Inhibitors market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Cancer Tubulin Inhibitors Market Share Analysis
Cancer Tubulin Inhibitors market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Cancer Tubulin Inhibitors business, the date to enter into the Cancer Tubulin Inhibitors market, Cancer Tubulin Inhibitors product introduction, recent developments, etc.

The major vendors covered:
Abraxis Biosciences
Agensys
Amgen
Celgene
Eagle Pharmaceuticals
Endocyte
Genentech
Immunogen
Modra Pharmaceuticals
Pierre Fabre
Roche
Sanofi-Aventis
Seattle Genetics
Tocris Bioscience

レポート目次

---

1 Study Coverage
1.1 Cancer Tubulin Inhibitors Product Introduction
1.2 Market Segments
1.3 Key Cancer Tubulin Inhibitors Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Cancer Tubulin Inhibitors Market Size Growth Rate by Type
1.4.2 Docetaxel
1.4.3 Trastuzumab Emtansine
1.4.4 Abraxane
1.4.5 Brentuximab Vedotin
1.4.6 Cabazitaxel
1.5 Market by Application
1.5.1 Global Cancer Tubulin Inhibitors Market Size Growth Rate by Application
1.5.2 Non Small Cell Lung Cancer
1.5.3 Prostate Cancer
1.5.4 Breast Cancer
1.5.5 Colorectal Cancer
1.5.6 Ovarian Cancer
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Cancer Tubulin Inhibitors Market Size, Estimates and Forecasts
2.1.1 Global Cancer Tubulin Inhibitors Revenue 2015-2026
2.1.2 Global Cancer Tubulin Inhibitors Sales 2015-2026
2.2 Global Cancer Tubulin Inhibitors, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Cancer Tubulin Inhibitors Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Cancer Tubulin Inhibitors Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Cancer Tubulin Inhibitors Competitor Landscape by Players
3.1 Cancer Tubulin Inhibitors Sales by Manufacturers
3.1.1 Cancer Tubulin Inhibitors Sales by Manufacturers (2015-2020)
3.1.2 Cancer Tubulin Inhibitors Sales Market Share by Manufacturers (2015-2020)
3.2 Cancer Tubulin Inhibitors Revenue by Manufacturers
3.2.1 Cancer Tubulin Inhibitors Revenue by Manufacturers (2015-2020)
3.2.2 Cancer Tubulin Inhibitors Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Cancer Tubulin Inhibitors Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Cancer Tubulin Inhibitors Revenue in 2019
3.2.5 Global Cancer Tubulin Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Cancer Tubulin Inhibitors Price by Manufacturers
3.4 Cancer Tubulin Inhibitors Manufacturing Base Distribution, Product Types
3.4.1 Cancer Tubulin Inhibitors Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Cancer Tubulin Inhibitors Product Type
3.4.3 Date of International Manufacturers Enter into Cancer Tubulin Inhibitors Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Cancer Tubulin Inhibitors Market Size by Type (2015-2020)
4.1.1 Global Cancer Tubulin Inhibitors Sales by Type (2015-2020)
4.1.2 Global Cancer Tubulin Inhibitors Revenue by Type (2015-2020)
4.1.3 Cancer Tubulin Inhibitors Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Cancer Tubulin Inhibitors Market Size Forecast by Type (2021-2026)
4.2.1 Global Cancer Tubulin Inhibitors Sales Forecast by Type (2021-2026)
4.2.2 Global Cancer Tubulin Inhibitors Revenue Forecast by Type (2021-2026)
4.2.3 Cancer Tubulin Inhibitors Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Cancer Tubulin Inhibitors Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Cancer Tubulin Inhibitors Market Size by Application (2015-2020)
5.1.1 Global Cancer Tubulin Inhibitors Sales by Application (2015-2020)
5.1.2 Global Cancer Tubulin Inhibitors Revenue by Application (2015-2020)
5.1.3 Cancer Tubulin Inhibitors Price by Application (2015-2020)
5.2 Cancer Tubulin Inhibitors Market Size Forecast by Application (2021-2026)
5.2.1 Global Cancer Tubulin Inhibitors Sales Forecast by Application (2021-2026)
5.2.2 Global Cancer Tubulin Inhibitors Revenue Forecast by Application (2021-2026)
5.2.3 Global Cancer Tubulin Inhibitors Price Forecast by Application (2021-2026)

6 North America
6.1 North America Cancer Tubulin Inhibitors by Country
6.1.1 North America Cancer Tubulin Inhibitors Sales by Country
6.1.2 North America Cancer Tubulin Inhibitors Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Cancer Tubulin Inhibitors Market Facts & Figures by Type
6.3 North America Cancer Tubulin Inhibitors Market Facts & Figures by Application

7 Europe
7.1 Europe Cancer Tubulin Inhibitors by Country
7.1.1 Europe Cancer Tubulin Inhibitors Sales by Country
7.1.2 Europe Cancer Tubulin Inhibitors Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Cancer Tubulin Inhibitors Market Facts & Figures by Type
7.3 Europe Cancer Tubulin Inhibitors Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Cancer Tubulin Inhibitors by Region
8.1.1 Asia Pacific Cancer Tubulin Inhibitors Sales by Region
8.1.2 Asia Pacific Cancer Tubulin Inhibitors Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Cancer Tubulin Inhibitors Market Facts & Figures by Type
8.3 Asia Pacific Cancer Tubulin Inhibitors Market Facts & Figures by Application

9 Latin America
9.1 Latin America Cancer Tubulin Inhibitors by Country
9.1.1 Latin America Cancer Tubulin Inhibitors Sales by Country
9.1.2 Latin America Cancer Tubulin Inhibitors Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Cancer Tubulin Inhibitors Market Facts & Figures by Type
9.3 Central & South America Cancer Tubulin Inhibitors Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Cancer Tubulin Inhibitors by Country
10.1.1 Middle East and Africa Cancer Tubulin Inhibitors Sales by Country
10.1.2 Middle East and Africa Cancer Tubulin Inhibitors Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Cancer Tubulin Inhibitors Market Facts & Figures by Type
10.3 Middle East and Africa Cancer Tubulin Inhibitors Market Facts & Figures by Application

11 Company Profiles
11.1 Abraxis Biosciences
11.1.1 Abraxis Biosciences Corporation Information
11.1.2 Abraxis Biosciences Description and Business Overview
11.1.3 Abraxis Biosciences Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Abraxis Biosciences Cancer Tubulin Inhibitors Products Offered
11.1.5 Abraxis Biosciences Related Developments
11.2 Agensys
11.2.1 Agensys Corporation Information
11.2.2 Agensys Description and Business Overview
11.2.3 Agensys Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Agensys Cancer Tubulin Inhibitors Products Offered
11.2.5 Agensys Related Developments
11.3 Amgen
11.3.1 Amgen Corporation Information
11.3.2 Amgen Description and Business Overview
11.3.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Amgen Cancer Tubulin Inhibitors Products Offered
11.3.5 Amgen Related Developments
11.4 Celgene
11.4.1 Celgene Corporation Information
11.4.2 Celgene Description and Business Overview
11.4.3 Celgene Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Celgene Cancer Tubulin Inhibitors Products Offered
11.4.5 Celgene Related Developments
11.5 Eagle Pharmaceuticals
11.5.1 Eagle Pharmaceuticals Corporation Information
11.5.2 Eagle Pharmaceuticals Description and Business Overview
11.5.3 Eagle Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Eagle Pharmaceuticals Cancer Tubulin Inhibitors Products Offered
11.5.5 Eagle Pharmaceuticals Related Developments
11.6 Endocyte
11.6.1 Endocyte Corporation Information
11.6.2 Endocyte Description and Business Overview
11.6.3 Endocyte Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Endocyte Cancer Tubulin Inhibitors Products Offered
11.6.5 Endocyte Related Developments
11.7 Genentech
11.7.1 Genentech Corporation Information
11.7.2 Genentech Description and Business Overview
11.7.3 Genentech Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Genentech Cancer Tubulin Inhibitors Products Offered
11.7.5 Genentech Related Developments
11.8 Immunogen
11.8.1 Immunogen Corporation Information
11.8.2 Immunogen Description and Business Overview
11.8.3 Immunogen Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Immunogen Cancer Tubulin Inhibitors Products Offered
11.8.5 Immunogen Related Developments
11.9 Modra Pharmaceuticals
11.9.1 Modra Pharmaceuticals Corporation Information
11.9.2 Modra Pharmaceuticals Description and Business Overview
11.9.3 Modra Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Modra Pharmaceuticals Cancer Tubulin Inhibitors Products Offered
11.9.5 Modra Pharmaceuticals Related Developments
11.10 Pierre Fabre
11.10.1 Pierre Fabre Corporation Information
11.10.2 Pierre Fabre Description and Business Overview
11.10.3 Pierre Fabre Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Pierre Fabre Cancer Tubulin Inhibitors Products Offered
11.10.5 Pierre Fabre Related Developments
11.1 Abraxis Biosciences
11.1.1 Abraxis Biosciences Corporation Information
11.1.2 Abraxis Biosciences Description and Business Overview
11.1.3 Abraxis Biosciences Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Abraxis Biosciences Cancer Tubulin Inhibitors Products Offered
11.1.5 Abraxis Biosciences Related Developments
11.12 Sanofi-Aventis
11.12.1 Sanofi-Aventis Corporation Information
11.12.2 Sanofi-Aventis Description and Business Overview
11.12.3 Sanofi-Aventis Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Sanofi-Aventis Products Offered
11.12.5 Sanofi-Aventis Related Developments
11.13 Seattle Genetics
11.13.1 Seattle Genetics Corporation Information
11.13.2 Seattle Genetics Description and Business Overview
11.13.3 Seattle Genetics Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Seattle Genetics Products Offered
11.13.5 Seattle Genetics Related Developments
11.14 Tocris Bioscience
11.14.1 Tocris Bioscience Corporation Information
11.14.2 Tocris Bioscience Description and Business Overview
11.14.3 Tocris Bioscience Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Tocris Bioscience Products Offered
11.14.5 Tocris Bioscience Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Cancer Tubulin Inhibitors Market Estimates and Projections by Region
12.1.1 Global Cancer Tubulin Inhibitors Sales Forecast by Regions 2021-2026
12.1.2 Global Cancer Tubulin Inhibitors Revenue Forecast by Regions 2021-2026
12.2 North America Cancer Tubulin Inhibitors Market Size Forecast (2021-2026)
12.2.1 North America: Cancer Tubulin Inhibitors Sales Forecast (2021-2026)
12.2.2 North America: Cancer Tubulin Inhibitors Revenue Forecast (2021-2026)
12.2.3 North America: Cancer Tubulin Inhibitors Market Size Forecast by Country (2021-2026)
12.3 Europe Cancer Tubulin Inhibitors Market Size Forecast (2021-2026)
12.3.1 Europe: Cancer Tubulin Inhibitors Sales Forecast (2021-2026)
12.3.2 Europe: Cancer Tubulin Inhibitors Revenue Forecast (2021-2026)
12.3.3 Europe: Cancer Tubulin Inhibitors Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Cancer Tubulin Inhibitors Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Cancer Tubulin Inhibitors Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Cancer Tubulin Inhibitors Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Cancer Tubulin Inhibitors Market Size Forecast by Region (2021-2026)
12.5 Latin America Cancer Tubulin Inhibitors Market Size Forecast (2021-2026)
12.5.1 Latin America: Cancer Tubulin Inhibitors Sales Forecast (2021-2026)
12.5.2 Latin America: Cancer Tubulin Inhibitors Revenue Forecast (2021-2026)
12.5.3 Latin America: Cancer Tubulin Inhibitors Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Cancer Tubulin Inhibitors Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Cancer Tubulin Inhibitors Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Cancer Tubulin Inhibitors Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Cancer Tubulin Inhibitors Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Cancer Tubulin Inhibitors Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Cancer Tubulin Inhibitors Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Cancer Tubulin Inhibitors Market Segments
Table 2. Ranking of Global Top Cancer Tubulin Inhibitors Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Cancer Tubulin Inhibitors Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Docetaxel
Table 5. Major Manufacturers of Trastuzumab Emtansine
Table 6. Major Manufacturers of Abraxane
Table 7. Major Manufacturers of Brentuximab Vedotin
Table 8. Major Manufacturers of Cabazitaxel
Table 9. Global Cancer Tubulin Inhibitors Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 10. Global Cancer Tubulin Inhibitors Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 11. Global Cancer Tubulin Inhibitors Sales by Regions 2015-2020 (K Pcs)
Table 12. Global Cancer Tubulin Inhibitors Sales Market Share by Regions (2015-2020)
Table 13. Global Cancer Tubulin Inhibitors Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Cancer Tubulin Inhibitors Sales by Manufacturers (2015-2020) (K Pcs)
Table 15. Global Cancer Tubulin Inhibitors Sales Share by Manufacturers (2015-2020)
Table 16. Global Cancer Tubulin Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Cancer Tubulin Inhibitors by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer Tubulin Inhibitors as of 2019)
Table 18. Cancer Tubulin Inhibitors Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Cancer Tubulin Inhibitors Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Cancer Tubulin Inhibitors Price (2015-2020) (USD/Pcs)
Table 21. Cancer Tubulin Inhibitors Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Cancer Tubulin Inhibitors Product Type
Table 23. Date of International Manufacturers Enter into Cancer Tubulin Inhibitors Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Cancer Tubulin Inhibitors Sales by Type (2015-2020) (K Pcs)
Table 26. Global Cancer Tubulin Inhibitors Sales Share by Type (2015-2020)
Table 27. Global Cancer Tubulin Inhibitors Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Cancer Tubulin Inhibitors Revenue Share by Type (2015-2020)
Table 29. Cancer Tubulin Inhibitors Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 30. Global Cancer Tubulin Inhibitors Sales by Application (2015-2020) (K Pcs)
Table 31. Global Cancer Tubulin Inhibitors Sales Share by Application (2015-2020)
Table 32. North America Cancer Tubulin Inhibitors Sales by Country (2015-2020) (K Pcs)
Table 33. North America Cancer Tubulin Inhibitors Sales Market Share by Country (2015-2020)
Table 34. North America Cancer Tubulin Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Cancer Tubulin Inhibitors Revenue Market Share by Country (2015-2020)
Table 36. North America Cancer Tubulin Inhibitors Sales by Type (2015-2020) (K Pcs)
Table 37. North America Cancer Tubulin Inhibitors Sales Market Share by Type (2015-2020)
Table 38. North America Cancer Tubulin Inhibitors Sales by Application (2015-2020) (K Pcs)
Table 39. North America Cancer Tubulin Inhibitors Sales Market Share by Application (2015-2020)
Table 40. Europe Cancer Tubulin Inhibitors Sales by Country (2015-2020) (K Pcs)
Table 41. Europe Cancer Tubulin Inhibitors Sales Market Share by Country (2015-2020)
Table 42. Europe Cancer Tubulin Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Cancer Tubulin Inhibitors Revenue Market Share by Country (2015-2020)
Table 44. Europe Cancer Tubulin Inhibitors Sales by Type (2015-2020) (K Pcs)
Table 45. Europe Cancer Tubulin Inhibitors Sales Market Share by Type (2015-2020)
Table 46. Europe Cancer Tubulin Inhibitors Sales by Application (2015-2020) (K Pcs)
Table 47. Europe Cancer Tubulin Inhibitors Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Cancer Tubulin Inhibitors Sales by Region (2015-2020) (K Pcs)
Table 49. Asia Pacific Cancer Tubulin Inhibitors Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Cancer Tubulin Inhibitors Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Cancer Tubulin Inhibitors Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Cancer Tubulin Inhibitors Sales by Type (2015-2020) (K Pcs)
Table 53. Asia Pacific Cancer Tubulin Inhibitors Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Cancer Tubulin Inhibitors Sales by Application (2015-2020) (K Pcs)
Table 55. Asia Pacific Cancer Tubulin Inhibitors Sales Market Share by Application (2015-2020)
Table 56. Latin America Cancer Tubulin Inhibitors Sales by Country (2015-2020) (K Pcs)
Table 57. Latin America Cancer Tubulin Inhibitors Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Cancer Tubulin Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Cancer Tubulin Inhibitors Revenue Market Share by Country (2015-2020)
Table 60. Latin America Cancer Tubulin Inhibitors Sales by Type (2015-2020) (K Pcs)
Table 61. Latin America Cancer Tubulin Inhibitors Sales Market Share by Type (2015-2020)
Table 62. Latin America Cancer Tubulin Inhibitors Sales by Application (2015-2020) (K Pcs)
Table 63. Latin America Cancer Tubulin Inhibitors Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Cancer Tubulin Inhibitors Sales by Country (2015-2020) (K Pcs)
Table 65. Middle East and Africa Cancer Tubulin Inhibitors Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Cancer Tubulin Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Cancer Tubulin Inhibitors Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Cancer Tubulin Inhibitors Sales by Type (2015-2020) (K Pcs)
Table 69. Middle East and Africa Cancer Tubulin Inhibitors Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Cancer Tubulin Inhibitors Sales by Application (2015-2020) (K Pcs)
Table 71. Middle East and Africa Cancer Tubulin Inhibitors Sales Market Share by Application (2015-2020)
Table 72. Abraxis Biosciences Corporation Information
Table 73. Abraxis Biosciences Description and Major Businesses
Table 74. Abraxis Biosciences Cancer Tubulin Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 75. Abraxis Biosciences Product
Table 76. Abraxis Biosciences Recent Development
Table 77. Agensys Corporation Information
Table 78. Agensys Description and Major Businesses
Table 79. Agensys Cancer Tubulin Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 80. Agensys Product
Table 81. Agensys Recent Development
Table 82. Amgen Corporation Information
Table 83. Amgen Description and Major Businesses
Table 84. Amgen Cancer Tubulin Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 85. Amgen Product
Table 86. Amgen Recent Development
Table 87. Celgene Corporation Information
Table 88. Celgene Description and Major Businesses
Table 89. Celgene Cancer Tubulin Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 90. Celgene Product
Table 91. Celgene Recent Development
Table 92. Eagle Pharmaceuticals Corporation Information
Table 93. Eagle Pharmaceuticals Description and Major Businesses
Table 94. Eagle Pharmaceuticals Cancer Tubulin Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 95. Eagle Pharmaceuticals Product
Table 96. Eagle Pharmaceuticals Recent Development
Table 97. Endocyte Corporation Information
Table 98. Endocyte Description and Major Businesses
Table 99. Endocyte Cancer Tubulin Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 100. Endocyte Product
Table 101. Endocyte Recent Development
Table 102. Genentech Corporation Information
Table 103. Genentech Description and Major Businesses
Table 104. Genentech Cancer Tubulin Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 105. Genentech Product
Table 106. Genentech Recent Development
Table 107. Immunogen Corporation Information
Table 108. Immunogen Description and Major Businesses
Table 109. Immunogen Cancer Tubulin Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 110. Immunogen Product
Table 111. Immunogen Recent Development
Table 112. Modra Pharmaceuticals Corporation Information
Table 113. Modra Pharmaceuticals Description and Major Businesses
Table 114. Modra Pharmaceuticals Cancer Tubulin Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 115. Modra Pharmaceuticals Product
Table 116. Modra Pharmaceuticals Recent Development
Table 117. Pierre Fabre Corporation Information
Table 118. Pierre Fabre Description and Major Businesses
Table 119. Pierre Fabre Cancer Tubulin Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 120. Pierre Fabre Product
Table 121. Pierre Fabre Recent Development
Table 122. Roche Corporation Information
Table 123. Roche Description and Major Businesses
Table 124. Roche Cancer Tubulin Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 125. Roche Product
Table 126. Roche Recent Development
Table 127. Sanofi-Aventis Corporation Information
Table 128. Sanofi-Aventis Description and Major Businesses
Table 129. Sanofi-Aventis Cancer Tubulin Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 130. Sanofi-Aventis Product
Table 131. Sanofi-Aventis Recent Development
Table 132. Seattle Genetics Corporation Information
Table 133. Seattle Genetics Description and Major Businesses
Table 134. Seattle Genetics Cancer Tubulin Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 135. Seattle Genetics Product
Table 136. Seattle Genetics Recent Development
Table 137. Tocris Bioscience Corporation Information
Table 138. Tocris Bioscience Description and Major Businesses
Table 139. Tocris Bioscience Cancer Tubulin Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 140. Tocris Bioscience Product
Table 141. Tocris Bioscience Recent Development
Table 142. Global Cancer Tubulin Inhibitors Sales Forecast by Regions (2021-2026) (K Pcs)
Table 143. Global Cancer Tubulin Inhibitors Sales Market Share Forecast by Regions (2021-2026)
Table 144. Global Cancer Tubulin Inhibitors Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 145. Global Cancer Tubulin Inhibitors Revenue Market Share Forecast by Regions (2021-2026)
Table 146. North America: Cancer Tubulin Inhibitors Sales Forecast by Country (2021-2026) (K Pcs)
Table 147. North America: Cancer Tubulin Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 148. Europe: Cancer Tubulin Inhibitors Sales Forecast by Country (2021-2026) (K Pcs)
Table 149. Europe: Cancer Tubulin Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 150. Asia Pacific: Cancer Tubulin Inhibitors Sales Forecast by Region (2021-2026) (K Pcs)
Table 151. Asia Pacific: Cancer Tubulin Inhibitors Revenue Forecast by Region (2021-2026) (US$ Million)
Table 152. Latin America: Cancer Tubulin Inhibitors Sales Forecast by Country (2021-2026) (K Pcs)
Table 153. Latin America: Cancer Tubulin Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 154. Middle East and Africa: Cancer Tubulin Inhibitors Sales Forecast by Country (2021-2026) (K Pcs)
Table 155. Middle East and Africa: Cancer Tubulin Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 156. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 157. Key Challenges
Table 158. Market Risks
Table 159. Main Points Interviewed from Key Cancer Tubulin Inhibitors Players
Table 160. Cancer Tubulin Inhibitors Customers List
Table 161. Cancer Tubulin Inhibitors Distributors List
Table 162. Research Programs/Design for This Report
Table 163. Key Data Information from Secondary Sources
Table 164. Key Data Information from Primary Sources
List of Figures
Figure 1. Cancer Tubulin Inhibitors Product Picture
Figure 2. Global Cancer Tubulin Inhibitors Sales Market Share by Type in 2020 & 2026
Figure 3. Docetaxel Product Picture
Figure 4. Trastuzumab Emtansine Product Picture
Figure 5. Abraxane Product Picture
Figure 6. Brentuximab Vedotin Product Picture
Figure 7. Cabazitaxel Product Picture
Figure 8. Global Cancer Tubulin Inhibitors Sales Market Share by Application in 2020 & 2026
Figure 9. Non Small Cell Lung Cancer
Figure 10. Prostate Cancer
Figure 11. Breast Cancer
Figure 12. Colorectal Cancer
Figure 13. Ovarian Cancer
Figure 14. Cancer Tubulin Inhibitors Report Years Considered
Figure 15. Global Cancer Tubulin Inhibitors Market Size 2015-2026 (US$ Million)
Figure 16. Global Cancer Tubulin Inhibitors Sales 2015-2026 (K Pcs)
Figure 17. Global Cancer Tubulin Inhibitors Market Size Market Share by Region: 2020 Versus 2026
Figure 18. Global Cancer Tubulin Inhibitors Sales Market Share by Region (2015-2020)
Figure 19. Global Cancer Tubulin Inhibitors Sales Market Share by Region in 2019
Figure 20. Global Cancer Tubulin Inhibitors Revenue Market Share by Region (2015-2020)
Figure 21. Global Cancer Tubulin Inhibitors Revenue Market Share by Region in 2019
Figure 22. Global Cancer Tubulin Inhibitors Sales Share by Manufacturer in 2019
Figure 23. The Top 10 and 5 Players Market Share by Cancer Tubulin Inhibitors Revenue in 2019
Figure 24. Cancer Tubulin Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 25. Global Cancer Tubulin Inhibitors Sales Market Share by Type (2015-2020)
Figure 26. Global Cancer Tubulin Inhibitors Sales Market Share by Type in 2019
Figure 27. Global Cancer Tubulin Inhibitors Revenue Market Share by Type (2015-2020)
Figure 28. Global Cancer Tubulin Inhibitors Revenue Market Share by Type in 2019
Figure 29. Global Cancer Tubulin Inhibitors Market Share by Price Range (2015-2020)
Figure 30. Global Cancer Tubulin Inhibitors Sales Market Share by Application (2015-2020)
Figure 31. Global Cancer Tubulin Inhibitors Sales Market Share by Application in 2019
Figure 32. Global Cancer Tubulin Inhibitors Revenue Market Share by Application (2015-2020)
Figure 33. Global Cancer Tubulin Inhibitors Revenue Market Share by Application in 2019
Figure 34. North America Cancer Tubulin Inhibitors Sales Growth Rate 2015-2020 (K Pcs)
Figure 35. North America Cancer Tubulin Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 36. North America Cancer Tubulin Inhibitors Sales Market Share by Country in 2019
Figure 37. North America Cancer Tubulin Inhibitors Revenue Market Share by Country in 2019
Figure 38. U.S. Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 39. U.S. Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. Canada Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 41. Canada Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 42. North America Cancer Tubulin Inhibitors Market Share by Type in 2019
Figure 43. North America Cancer Tubulin Inhibitors Market Share by Application in 2019
Figure 44. Europe Cancer Tubulin Inhibitors Sales Growth Rate 2015-2020 (K Pcs)
Figure 45. Europe Cancer Tubulin Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 46. Europe Cancer Tubulin Inhibitors Sales Market Share by Country in 2019
Figure 47. Europe Cancer Tubulin Inhibitors Revenue Market Share by Country in 2019
Figure 48. Germany Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. Germany Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. France Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. France Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. U.K. Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. U.K. Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Italy Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Italy Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Russia Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 57. Russia Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. Europe Cancer Tubulin Inhibitors Market Share by Type in 2019
Figure 59. Europe Cancer Tubulin Inhibitors Market Share by Application in 2019
Figure 60. Asia Pacific Cancer Tubulin Inhibitors Sales Growth Rate 2015-2020 (K Pcs)
Figure 61. Asia Pacific Cancer Tubulin Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 62. Asia Pacific Cancer Tubulin Inhibitors Sales Market Share by Region in 2019
Figure 63. Asia Pacific Cancer Tubulin Inhibitors Revenue Market Share by Region in 2019
Figure 64. China Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. China Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. Japan Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. Japan Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. South Korea Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. South Korea Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. India Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. India Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Australia Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Australia Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Taiwan Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Taiwan Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Indonesia Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Indonesia Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Thailand Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Thailand Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Malaysia Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Malaysia Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Philippines Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Philippines Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Vietnam Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 85. Vietnam Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 86. Asia Pacific Cancer Tubulin Inhibitors Market Share by Type in 2019
Figure 87. Asia Pacific Cancer Tubulin Inhibitors Market Share by Application in 2019
Figure 88. Latin America Cancer Tubulin Inhibitors Sales Growth Rate 2015-2020 (K Pcs)
Figure 89. Latin America Cancer Tubulin Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 90. Latin America Cancer Tubulin Inhibitors Sales Market Share by Country in 2019
Figure 91. Latin America Cancer Tubulin Inhibitors Revenue Market Share by Country in 2019
Figure 92. Mexico Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Mexico Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Brazil Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Brazil Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Argentina Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 97. Argentina Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 98. Latin America Cancer Tubulin Inhibitors Market Share by Type in 2019
Figure 99. Latin America Cancer Tubulin Inhibitors Market Share by Application in 2019
Figure 100. Middle East and Africa Cancer Tubulin Inhibitors Sales Growth Rate 2015-2020 (K Pcs)
Figure 101. Middle East and Africa Cancer Tubulin Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 102. Middle East and Africa Cancer Tubulin Inhibitors Sales Market Share by Country in 2019
Figure 103. Middle East and Africa Cancer Tubulin Inhibitors Revenue Market Share by Country in 2019
Figure 104. Turkey Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. Turkey Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Saudi Arabia Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 107. Saudi Arabia Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. U.A.E Cancer Tubulin Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 109. U.A.E Cancer Tubulin Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 110. Middle East and Africa Cancer Tubulin Inhibitors Market Share by Type in 2019
Figure 111. Middle East and Africa Cancer Tubulin Inhibitors Market Share by Application in 2019
Figure 112. North America Cancer Tubulin Inhibitors Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. North America Cancer Tubulin Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Europe Cancer Tubulin Inhibitors Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Europe Cancer Tubulin Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Asia Pacific Cancer Tubulin Inhibitors Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Asia Pacific Cancer Tubulin Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Latin America Cancer Tubulin Inhibitors Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 119. Latin America Cancer Tubulin Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Middle East and Africa Cancer Tubulin Inhibitors Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 121. Middle East and Africa Cancer Tubulin Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 122. Porter's Five Forces Analysis
Figure 123. Channels of Distribution
Figure 124. Distributors Profiles
Figure 125. Bottom-up and Top-down Approaches for This Report
Figure 126. Data Triangulation
Figure 127. Key Executives Interviewed

---